Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Colorectal Neoplasms 9Pancreatic Neoplasms 8Rectal Neoplasms 5Urinary Bladder Neoplasms 4Stomach Neoplasms 4Colonic Neoplasms 3Adenocarcinoma Of Esophagus 3Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Neoplasm Metastasis 2Clinical Stage I Gastric Cancer AJCC v8 2Cholangiocarcinoma 2Appendiceal Neoplasms 2Anus Neoplasms 2Uterine Neoplasms 1Tongue Neoplasms 1Sinonasal undifferentiated carcinoma 1Salivary Gland Neoplasms 1Peritoneal Neoplasms 1Paranasal Sinus Neoplasms 1Pancreatic Intraductal Neoplasms 1Pancreatic Adenocarcinoma 1PRETEXT I Hepatoblastoma 1Oropharyngeal Neoplasms 1Neoplasms 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Metastatic Small Intestinal Adenocarcinoma 1Lymphoid Interstitial Pneumonia 1Laryngeal Neoplasms 1

Interventions

pembrolizumab 90Blood Specimen Collection 41Cyclophosphamide 37Bevacizumab 36Nivolumab 35Standard of Care 32Carboplatin 31Surveys and Questionnaires 29Paclitaxel 27atezolizumab 25Exercise 25Pemetrexed 24Gemcitabine 23Cisplatin 23Fluorouracil 22Radiotherapy 20Leucovorin 20Dexamethasone 20Docetaxel 19Oxaliplatin 18Rituximab 16Irinotecan 16Cetuximab 16dostarlimab 15Drug Therapy 15Doxorubicin 15Ipilimumab 14Biopsy 14130-nm albumin-bound paclitaxel 14fludarabine 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × dehydroftorafur × 1 year × Clear all
NCT03203525 2026-02-25

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
38 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡